KMID : 1148920140480010016
|
|
Nuclear Medicine and Molecular Imaging 2014 Volume.48 No. 1 p.16 ~ p.25
|
|
Intratumoral Metabolic Heterogeneity for Prediction of Disease Progression After Concurrent Chemoradiotherapy in Patients with Inoperable Stage III Non-Small-Cell Lung Cancer
|
|
Kang Sae-Ryung
Song Ho-Chun Byun Byung-Hyun Oh Jong-Ryool Kim Hyeon-Sik Hong Sun-Pyo Kwon Seong-Young Chong A-Ri Kim Ja-Hae Cho Sang-Geon Park Hee-Jeong Kim Young-Chul Ahn Sung-Ja Min Jung-Joon Bom Hee-Seung
|
|
Abstract
|
|
|
Purpose: We evaluated the value of variable 18F-FDG PET/CT parameters for the prediction of disease progression after concurrent chemoradiotherapy (CCRT) in patients with inoperable stage III non-small-cell lung cancer (NSCLC).
Methods: One hundred sixteen pretreatment FDG PET/CT scans of inoperable stage III NSCLC were retrospectively reviewed (stage IIIA: 51; stage IIIB: 65). The volume of interest was automatically drawn for each primary lung tumor, and PET parameters were assessed as follows: maximum standardized uptake value (SUVmax), metabolic tumor volume (MTV) using the boundaries presenting SUV intensity exceeding 3.0, and the area under the curve of the cumulative SUV-volume histograms (AUC-CSH), which is known to reflect the tumor heterogeneity. Progression-free survival (PFS), locoregional recurrence-free survival (LRFS), and distant metastasis-free survival (DMFS) were compared with each PET and clinical parameters by univariate and multivariate survival analysis.
Results: In the ROC analysis, the optimal cutoff values of SUVmax, MTV (cm3), and AUC-CSH for prediction of PFS were determined as 21.5, 27.7, and 4,800, respectively. In univariate analysis, PFS was statistically significantly reduced in those with AUC-CSH?4,800 (p?=?0.004). In multivariate analysis, AUC-CSH and SUVmax were statistically significant independent prognostic factors (HR 3.35, 95 % CI 1.79?6.28, p?0.001; HR 0.25, 95 % CI 0.09?0.70, p?=?0.008, respectively). Multivariate analysis showed that AUC-CSH was the most significant independent prognostic factor for LRFS and DMFS (HR 3.27, 95 % CI 1.54?6.94, p?=?0.002; HR 2.79, 95 % CI 1.42?5.50, p?=?0.003).
Conclusions: Intratumoral metabolic heterogeneity of primary lung tumor in 18F-FDG PET/CT can predict disease progression after CCRT in inoperable stage III NSCLC.
|
|
KEYWORD
|
|
Non-small-cell lung cancer, Intratumoral heterogeneity, Prognosis, F-18 FDG PET
|
|
FullTexts / Linksout information
|
|
|
|
Listed journal information
|
|
|
|